Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q3 2013 · 10-Q
Revenue$9.49M$9.49M+1,010.0% vs Q3 2012 Net Income-$30.88M-$30.88MN/M vs Q3 2012 EPS Diluted-$0.64-$0.64N/M vs Q3 2012 Operating Income$765,644N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,888,875N/M Margins · derivedOperating margin8.1%+744.2 pt vs Q3 2012
Net margin-325.5%+449.3 pt vs Q3 2012
ended Sep 30, 2013 · filed Nov 12, 2013 · 43 d after period end